MYCBP

MYCBP Full Name

c-myc binding protein

MYCBP Introduction

MYCBP, or c-Myc binding protein, is encoded by a conserved gene situated on human chromosome 1p33-p34.3, a region devoid of frequent chromosomal rearrangements in common cancers. The translated product is a small, intrinsically disordered protein of approximately 12 kDa, lacking classical enzymatic domains but rich in proline and glutamine residues. This structural flexibility enables it to adopt multiple conformations when engaging with different binding partners. Unlike globular proteins, MYCBP relies on short linear motifs for its interactions, allowing rapid on-off kinetics essential for transcriptional modulation. Its nuclear localization signal ensures predominant accumulation within the nucleoplasm, where it dynamically shuttles between chromatin-associated fractions and soluble pools.

Figure 1.MYCBP protein structure & domains.

Mechanism of Transcriptional Amplification
Rather than acting as a classical co-activator that recruits histone acetyltransferases, MYCBP enhances Myc-driven transcription through a unique stabilization mechanism. It binds directly to the Myc box II region, protecting the oncoprotein from ubiquitin-mediated proteasomal degradation, thereby extending its half-life. This prolonged presence allows Myc to sustain expression of its target genes, including those involved in ribosome biogenesis and nucleotide synthesis. Importantly, MYCBP does not increase Myc's DNA-binding affinity; instead, it potentiates the transcriptional output of already-bound Myc-MAX dimers. Structural studies suggest that MYCBP induces a conformational shift in Myc's transactivation domain, exposing residues critical for engaging the basal transcriptional machinery.

Pathological Implications and Therapeutic Prospects
Overexpression of MYCBP has been documented in high-grade gliomas, ovarian carcinomas, and mantle cell lymphomas, often correlating with elevated Myc target gene signatures and poor clinical outcomes. Knockdown experiments in cancer cell lines demonstrate reduced proliferation, increased apoptosis, and diminished xenograft tumor growth in murine models. Importantly, MYCBP appears to be dispensable for normal adult tissue homeostasis, as knockout mice exhibit no overt developmental defects. This differential dependency positions MYCBP as an attractive indirect target for Myc-driven malignancies, where direct Myc inhibition has proven challenging. Current preclinical efforts are focused on developing peptide-based disruptors that block the MYCBP-Myc interface, aiming to destabilize Myc without affecting its DNA-binding functions.

Alternate Names for MYCBP

MYCBP; c-myc binding protein; C-Myc-binding protein; associate of Myc 1; Amy-1; AW552132; AW742590; 5730488M09Rik;